Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago.

Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange ...

Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange ...

Given the accelerating sales growth of LIBTAYO and stabilization in the EYLEA franchise, investors bid up the price of Regeneron's stock by +4.5% on Tuesday. The company's robust performance makes ...

Secondly, to support the stock price, Regeneron management announced the authorization of an additional $3 billion, which will go towards a share buyback program. The New York-based company ...

Regeneron also is studying Libtayo as a combo therapy with the company’s fianlimab, going up against Keytruda, in first-line melanoma. “If these data confirm best-in-class activity in melanoma ...

Regeneron bought the global rights to the cancer drug from partner Sanofi in 2022. The company reported an adjusted profit of $12.07 per share in the quarter, above analysts' average estimate of ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per ...